secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2026-06-11T20:05:16+00:00
Accession:  0001193125-26-267487
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports 2026 annual meeting voting results
---------------------------------------------------------------

- At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.
- Directors William P. Quinn and Jakob Dupont elected as Class II members for three-year terms.
- Quinn: 349,358 for, 52,117 withheld; Dupont: 377,163 for, 24,312 withheld; 475,883 broker non-votes each.
- Ratification of PricewaterhouseCoopers as auditor for 2026: 768,336 for, 107,471 against, 1,551 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/bolt-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-267487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer